NYSE:RMD - ResMed Stock Price, Forecast & News

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

ResMed announced a quarterly dividend on Thursday, October 24th. Investors of record on Thursday, November 7th will be given a dividend of $0.39 per share on Thursday, December 12th. This represents a $1.56 dividend on an annualized basis and a yield of 0.97%. The ex-dividend date is Wednesday, November 6th. View ResMed's Dividend History.

ResMed Inc. (NYSE:RMD) issued its quarterly earnings data on Thursday, October, 24th. The medical equipment provider reported $0.93 earnings per share for the quarter, beating the consensus estimate of $0.87 by $0.06. The medical equipment provider had revenue of $681.06 million for the quarter, compared to analysts' expectations of $660.87 million. ResMed had a return on equity of 26.72% and a net margin of 15.52%. ResMed's revenue was up 15.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.81 EPS. View ResMed's Earnings History.

ResMed is scheduled to release their next quarterly earnings announcement on Thursday, January 30th 2020. View Earnings Estimates for ResMed.

ResMed will be holding an earnings conference call on Thursday, January 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

8 brokerages have issued 12 month target prices for ResMed's stock. Their forecasts range from $95.00 to $140.00. On average, they expect ResMed's share price to reach $118.33 in the next twelve months. This suggests that the stock has a possible downside of 26.6%. View Analyst Price Targets for ResMed.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ResMed.

News articles about RMD stock have trended positive on Friday, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. ResMed earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for ResMed.

Some companies that are related to ResMed include Medtronic (MDT), Abbott Laboratories (ABT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Varian Medical Systems (VAR), Steris (STE) and Insulet (PODD).

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include Walt Disney (DIS), Energy Transfer LP Unit (ET), Netflix (NFLX), Starbucks (SBUX), Visa (V), NVIDIA (NVDA), Mastercard (MA), AT&T (T), Adobe (ADBE) and Costco Wholesale (COST).

ResMed's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Welch & Forbes LLC (0.21%), Capital Investment Services of America Inc. (0.11%), Gateway Investment Advisers LLC (0.08%), Tandem Investment Advisors Inc. (0.05%), State of Alaska Department of Revenue (0.04%) and Coastline Trust Co (0.02%). Company insiders that own ResMed stock include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Richard Sulpizio, Robert Andrew Douglas and Ronald R Taylor. View Institutional Ownership Trends for ResMed.

RMD stock was sold by a variety of institutional investors in the last quarter, including Tandem Investment Advisors Inc., Gateway Investment Advisers LLC, Welch & Forbes LLC, IFM Investors Pty Ltd, Capital Investment Services of America Inc., Coastline Trust Co, We Are One Seven LLC and IBM Retirement Fund. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, James Hollingshead, John P Wareham, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor. View Insider Buying and Selling for ResMed.

RMD stock was acquired by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., State of Alaska Department of Revenue, Tuttle Tactical Management, Perigon Wealth Management LLC, DNB Asset Management AS, Boston Trust Walden Corp, Calamos Advisors LLC and AE Wealth Management LLC. View Insider Buying and Selling for ResMed.

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RMD stock can currently be purchased for approximately $161.24.

ResMed has a market capitalization of $23.18 billion and generates $2.61 billion in revenue each year. The medical equipment provider earns $404.59 million in net income (profit) each year or $3.64 on an earnings per share basis. ResMed employs 7,240 workers across the globe.View Additional Information About ResMed.

The official website for ResMed is http://www.resmed.com/.

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]